For patients aged 55 years or older at diagnosis, with a histologically classic GBM that is not located in midline structures and has no history of pre-existing lower-grade glioma, the lack of immunoreactivity for IDH1 p.R132H is sufficient to diagnose IDH-wildtype GBM [16]. The gene discussed is IDH2; the disease is glioblastoma.